vs
百利高（PRGO）与越洋钻探（RIG）财务数据对比。点击上方公司名可切换其他公司
百利高的季度营收约是越洋钻探的1.1倍（$1.1B vs $1.0B），越洋钻探净利率更高（2.4% vs -127.8%，领先130.2%），越洋钻探同比增速更快（9.6% vs -2.5%），越洋钻探自由现金流更多（$321.0M vs $148.6M），过去两年越洋钻探的营收复合增速更高（16.9% vs 1.3%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
越洋钻探（Transocean Ltd.）是按营收计全球规模最大的海上钻探承包商，总部位于瑞士施泰因豪森，起源于美国，目前在加拿大、美国、挪威、英国、印度、巴西、新加坡等20个国家设有办事机构，业务覆盖全球主要海上油气开采区域。
PRGO vs RIG — 直观对比
营收规模更大
PRGO
是对方的1.1倍
$1.0B
营收增速更快
RIG
高出12.1%
-2.5%
净利率更高
RIG
高出130.2%
-127.8%
自由现金流更多
RIG
多$172.4M
$148.6M
两年增速更快
RIG
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.0B |
| 净利润 | $-1.4B | $25.0M |
| 毛利率 | 32.6% | 42.0% |
| 营业利润率 | -116.0% | 23.0% |
| 净利率 | -127.8% | 2.4% |
| 营收同比 | -2.5% | 9.6% |
| 净利润同比 | -3093.9% | 257.1% |
| 每股收益（稀释后） | $-10.23 | $0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGORIG
| Q4 25 | $1.1B | $1.0B | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $1.1B | $988.0M | ||
| Q1 25 | $1.0B | $906.0M | ||
| Q4 24 | $1.1B | $952.0M | ||
| Q3 24 | $1.1B | $948.0M | ||
| Q2 24 | $1.1B | $861.0M | ||
| Q1 24 | $1.1B | $763.0M |
净利润PRGORIG
| Q4 25 | $-1.4B | $25.0M | ||
| Q3 25 | $7.5M | $-1.9B | ||
| Q2 25 | $-8.4M | $-938.0M | ||
| Q1 25 | $-6.4M | $-79.0M | ||
| Q4 24 | $-44.4M | $7.0M | ||
| Q3 24 | $-21.0M | $-494.0M | ||
| Q2 24 | $-108.4M | $-123.0M | ||
| Q1 24 | $2.0M | $98.0M |
毛利率PRGORIG
| Q4 25 | 32.6% | 42.0% | ||
| Q3 25 | 36.1% | 43.2% | ||
| Q2 25 | 34.4% | 39.4% | ||
| Q1 25 | 37.6% | 31.8% | ||
| Q4 24 | 33.9% | 39.2% | ||
| Q3 24 | 37.2% | 40.6% | ||
| Q2 24 | 37.0% | 38.0% | ||
| Q1 24 | 33.1% | 31.5% |
营业利润率PRGORIG
| Q4 25 | -116.0% | 23.0% | ||
| Q3 25 | 7.0% | -163.1% | ||
| Q2 25 | 4.3% | -97.6% | ||
| Q1 25 | 4.5% | 7.1% | ||
| Q4 24 | 10.0% | 13.7% | ||
| Q3 24 | 7.4% | -51.2% | ||
| Q2 24 | -2.5% | -6.9% | ||
| Q1 24 | -5.1% | -0.4% |
净利率PRGORIG
| Q4 25 | -127.8% | 2.4% | ||
| Q3 25 | 0.7% | -187.1% | ||
| Q2 25 | -0.8% | -94.9% | ||
| Q1 25 | -0.6% | -8.7% | ||
| Q4 24 | -3.9% | 0.7% | ||
| Q3 24 | -1.9% | -52.1% | ||
| Q2 24 | -10.2% | -14.3% | ||
| Q1 24 | 0.2% | 12.8% |
每股收益（稀释后）PRGORIG
| Q4 25 | $-10.23 | $0.13 | ||
| Q3 25 | $0.05 | $-2.00 | ||
| Q2 25 | $-0.06 | $-1.06 | ||
| Q1 25 | $-0.05 | $-0.11 | ||
| Q4 24 | $-0.32 | $-0.14 | ||
| Q3 24 | $-0.15 | $-0.58 | ||
| Q2 24 | $-0.79 | $-0.15 | ||
| Q1 24 | $0.01 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $620.0M |
| 总债务越低越好 | — | $5.2B |
| 股东权益账面价值 | $2.9B | $8.1B |
| 总资产 | $8.5B | $15.6B |
| 负债/权益比越低杠杆越低 | — | 0.64× |
8季度趋势，按日历期对齐
现金及短期投资PRGORIG
| Q4 25 | — | $620.0M | ||
| Q3 25 | $432.1M | $833.0M | ||
| Q2 25 | $454.2M | $377.0M | ||
| Q1 25 | $409.9M | $263.0M | ||
| Q4 24 | $558.8M | $560.0M | ||
| Q3 24 | $1.5B | $435.0M | ||
| Q2 24 | $542.8M | $475.0M | ||
| Q1 24 | $658.5M | $446.0M |
总债务PRGORIG
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $4.8B | ||
| Q2 25 | — | $5.9B | ||
| Q1 25 | — | $5.9B | ||
| Q4 24 | — | $6.2B | ||
| Q3 24 | — | $6.5B | ||
| Q2 24 | — | $6.8B | ||
| Q1 24 | — | $6.8B |
股东权益PRGORIG
| Q4 25 | $2.9B | $8.1B | ||
| Q3 25 | $4.4B | $8.1B | ||
| Q2 25 | $4.5B | $9.4B | ||
| Q1 25 | $4.4B | $10.2B | ||
| Q4 24 | $4.3B | $10.3B | ||
| Q3 24 | $4.6B | $10.2B | ||
| Q2 24 | $4.5B | $10.7B | ||
| Q1 24 | $4.7B | $10.5B |
总资产PRGORIG
| Q4 25 | $8.5B | $15.6B | ||
| Q3 25 | $10.1B | $16.2B | ||
| Q2 25 | $10.1B | $17.8B | ||
| Q1 25 | $9.8B | $19.0B | ||
| Q4 24 | $9.6B | $19.4B | ||
| Q3 24 | $11.2B | $19.5B | ||
| Q2 24 | $10.4B | $20.3B | ||
| Q1 24 | $10.6B | $19.9B |
负债/权益比PRGORIG
| Q4 25 | — | 0.64× | ||
| Q3 25 | — | 0.60× | ||
| Q2 25 | — | 0.63× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | $349.0M |
| 自由现金流经营现金流 - 资本支出 | $148.6M | $321.0M |
| 自由现金流率自由现金流/营收 | 13.4% | 30.8% |
| 资本支出强度资本支出/营收 | 2.4% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 13.96× |
| 过去12个月自由现金流最近4个季度 | $145.1M | $626.0M |
8季度趋势，按日历期对齐
经营现金流PRGORIG
| Q4 25 | $175.4M | $349.0M | ||
| Q3 25 | $51.7M | $246.0M | ||
| Q2 25 | $75.9M | $128.0M | ||
| Q1 25 | $-64.5M | $26.0M | ||
| Q4 24 | $312.6M | $206.0M | ||
| Q3 24 | $42.2M | $194.0M | ||
| Q2 24 | $9.5M | $133.0M | ||
| Q1 24 | $-1.4M | $-86.0M |
自由现金流PRGORIG
| Q4 25 | $148.6M | $321.0M | ||
| Q3 25 | $29.8M | $235.0M | ||
| Q2 25 | $56.7M | $104.0M | ||
| Q1 25 | $-90.0M | $-34.0M | ||
| Q4 24 | $274.9M | $177.0M | ||
| Q3 24 | $15.1M | $136.0M | ||
| Q2 24 | $-18.9M | $49.0M | ||
| Q1 24 | $-26.5M | $-169.0M |
自由现金流率PRGORIG
| Q4 25 | 13.4% | 30.8% | ||
| Q3 25 | 2.9% | 22.9% | ||
| Q2 25 | 5.4% | 10.5% | ||
| Q1 25 | -8.6% | -3.8% | ||
| Q4 24 | 24.2% | 18.6% | ||
| Q3 24 | 1.4% | 14.3% | ||
| Q2 24 | -1.8% | 5.7% | ||
| Q1 24 | -2.4% | -22.1% |
资本支出强度PRGORIG
| Q4 25 | 2.4% | 2.7% | ||
| Q3 25 | 2.1% | 1.1% | ||
| Q2 25 | 1.8% | 2.4% | ||
| Q1 25 | 2.4% | 6.6% | ||
| Q4 24 | 3.3% | 3.0% | ||
| Q3 24 | 2.5% | 6.1% | ||
| Q2 24 | 2.7% | 9.8% | ||
| Q1 24 | 2.3% | 10.9% |
现金转化率PRGORIG
| Q4 25 | — | 13.96× | ||
| Q3 25 | 6.89× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 29.43× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.70× | -0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
RIG
| Ultra Deepwater Floaters | $433.0M | 42% |
| BR | $236.0M | 23% |
| Other Geographical | $211.0M | 20% |
| Harsh Environment Floaters | $163.0M | 16% |
